Cyclopharm Limited · ASX:CYC
Cyclopharm — Shareholder Meeting (July 2020)
29 slides from Cyclopharm's shareholder meeting presentation, Jul 9, 2020
Slide 1: Cyclopharm AGM Presentation 2019 Financial Year Results
For personal use only Cyclopharm AGM Presentation 2019 Financial Year Results 9 July 2020 1
Slide 2: Safe Harbour Statement
For personal use only Safe Harbour Statement Certain views expressed here contain information derived from publicly available sources that have not been independently verified. The presentation includes certain statements, estimates and projections with respect to the anticipated future financial pe
Slide 3: Welcome
For personal use only Welcome David Heaney
Slide 4: Online Attendees – Question Process
For personal use only Online Attendees – Question Process • When the Question function is available, the Q&A icon will appear at the top of the app. • To send in a question, simply click in the ‘Ask a question’ box, type your question and the press the send arrow • Your question will be sent immedia
Slide 5: Online Attendees – Voting Process
For personal use only Online Attendees – Voting Process • When the poll is open, the vote will be accessible by selecting the voting icon at the top of the screen • To vote simply select the direction in which you would like to cast your vote, the selected option will change colour. • There is no su
Slide 6: Chairman's Address
For personal use only Chairman’s Address David Heaney
Slide 7: Managing Director's Address
For personal use only Managing Director’s Address James McBrayer
Slide 8: Cyclopharm Building for Growth
For personal use only CYCLOPHARM BUILDING FOR GROWTH Profitable & First in class Recurring USFDA Optionality Growing Technegas technology revenue approval expanding into MedTech generating sales from from high margin set to more than indications beyond 60 countries and consumable sales quadruple the
Slide 9: Building for Growth – Company Development
For personal use only Building for Growth – Company Development Technegas is a substantially de‐risked commercial proposition with significant Technegas Revenue by Region ($ 000’s) upside in the USA market with target USFDA approval by 2021 16,000 14,000 Total global sales of $118 m from 2010 12,0
Slide 10: FY2019 Results Highlights
For personal use only FY2019 Results Highlights Group Sales Revenue $14.08 million ‐ an increase of 5% Gross Margin $11.62 million – an increase of 7% Gross Margin % 82.5% Net Loss After Tax ($2.91) million including USFDA investment Dividends 1.0 cents per share Underlying PBT1 $0.89 million FDA Tr
Slide 11: FY2019 Operational Highlights
For personal use only FY2019 Operational Highlights Technegas Record revenues recorded in the key markets of Canada and France USFDA All internal documentation completed with a Q1 2020 USFDA submission USA Commercialisation USA entity established Indication Expansion HMRI completes recruitment – New
Slide 12: Our Strategic Priorities
For personal use only Our Strategic Priorities CYC has clear strategy to leverage our position as a leading player in the global nuclear medicine imaging market and exponentially larger lung health space to expand the use of our proprietary products and introduce new innovative technology. We will d
Slide 13: Ultralute Update
For personal use only Ultralute Update • Ultralute™ has the potential to bring significant cost savings in the delivery of pharmaceuticals used in nuclear medicine by extending the useful life of Molybdenum‐99 (Mo‐99) generators by up to 50%. • Registered as a Class 1 Medical Device on the ARTG • De
Slide 14: Technegas: World's Best Functional Lung Ventilation Imaging Agent
For personal use only Technegas: World’s Best Functional Lung Ventilation Imaging Agent Patient inhales extremely small carbon particles labeled with 99mTechnetium1 The small size and hydrophobic properties demonstrates gas like‐ behavior and alveoli deposition into the lungs2‐3 Clinicians can visua
Slide 15: Coming to America
For personal use only Coming to America 15 Technegas® is not commercially available in the USA
Slide 16: Technegas – USA Market Opportunity
For personal use only Technegas – USA Market Opportunity 4,000,000 patient procedures conducted in the USA per annum to diagnose pulmonary embolism (15% Nuclear Medicine – 85% CTPA) 600,000 Nuclear Medicine Ventilation procedures equals $90m USD 600K Nuclear Medicine Ventilation Target market
Slide 17: Technegas FDA Clinical Trial Process and Design
For personal use only Technegas FDA Clinical Trial Process and Design USFDA Clinical trial1 registered at: https://clinicaltrials.gov/ct2/show/NCT03054870?term=technegas&rank=1 Non‐inferiority structural ventilation study comparing Xe133 vs. Technegas1 Approval Planned 240 patient study at 9 clinica
Slide 18: USA 2020 Commercialisation Plan
For personal use only USA 2020 Commercialisation Plan Build Inventory People Materials Resource Hire Key USA Personnel Planning underway with to include Sales and production targeting 200 Service Techengas generators roll‐ out per anum USFDA Regulatory Secure Customer Distribution Approval Commitmen
Slide 19: Beyond PE: clinical initiatives
For personal use only Beyond PE : clinical initiatives Clinical Trials Sponsored by Cyclomedica • Hunter Medical Research Institute (Newcastle, AU): Diagnosis and response PATIENT MANAGEMENT & SCREENING to therapy in severe asthma and COPD1 Response to Therapy and Personalized Medicine • Woolcock In
Slide 20: Three Value Horizons
For personal use only Three Value Horizons Horizon 1 Horizon 2 Horizon 3 0 to 5 Years 3 to 8 Years >8 Years Innovate Beyond PE Establish USA Convert CTPA Half billion Enterprise Value Double existing Nuc Med combined sufferers of Asthma and 80% Conversion of Nuc Chronic Obstructive Pulmonary Med Pro
Slide 21: Cyclopharm Investment Case
For personal use only CYCLOPHARM INVESTMENT CASE Profitable & First in class Recurring USFDA approval Optionality Growing proprietary product revenue set to quadruple the size into indications beyond MedTech sales to 60 countries from consumables of the existing PE business PE into chronic with over
Slide 22: Thank You & Business Q&A
For personal use only Cyclopharm Thank You & Business Q&A 22
Slide 23: AGM Formal Business
For personal use only AGM Formal Business
Slide 24: CYC AGM 2020 Resolutions – Remuneration Report
For personal use only CYC AGM 2020 Resolutions 1 That the Remuneration Report as set out in the Annual Report of the Company for the financial year ended 31 December 2019 be adopted. Questions? 24
Slide 25: CYC AGM 2020 Resolutions – Re-election of Director
For personal use only CYC AGM 2020 Resolutions 2 That, for the purposes of ASX Listing Rule 14.5 and for all other purposes, Mr David James Heaney, who retires at the close of this Annual General Meeting and, being eligible, and having consented to act, be re‐elected as a Director of the Company. Qu
Slide 26: CYC AGM 2020 Resolutions – Share Issue to Managing Director
For personal use only CYC AGM 2020 Resolutions 3 That pursuant to ASX Listing Rules 10.14 and 10.15, approval is given for the Directors to issue and allot a total 1,015,500 ordinary shares to Mr James McBrayer and/or his nominee, acting in his capacity as the Managing Director of the Company, and t
Slide 27: 2020 AGM Formal Business – Proxies Received
For personal use only 2020 AGM Formal Business Resolution Proxies Received *Includes Open Useable Proxies that have instructed the Chairman to vote on their behalf and have voted in favour of the resolution.
Slide 28: Votes are Being Tabulated
For personal use only Technegas: World’s Best Functional Lung Ventilation Imaging Agent Votes are Being Tabulated 28
Slide 29: Cyclopharm Thank You
For personal use only Cyclopharm Thank You 29